Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase

被引:680
作者
Kubicek, Stefan
O'Sullivan, Roderick J.
August, E. Michael
Hickey, Eugene R.
Zhan, Qiang
Teodoro, Miguel L.
Rea, Stephen
Mechtler, Karl
Kowalski, Jennifer A.
Homon, Carol Ann
Kelly, Terence A.
Jenuwein, Thomas
机构
[1] Vienna Bioctr, Res Inst Mol Pathol, A-1030 Vienna, Austria
[2] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA
关键词
D O I
10.1016/j.molcel.2007.01.017
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Histone lysine methylation has important roles in the organization of chromatin domains and the regulation of gene expression. To analyze its function and modulate its activity, we screened for specific inhibitors against histone lysine methyltransferases (HMTases) using recombinant G9a as the target enzyme. From a chemical library comprising 125,000 preselected compounds, seven hits were identified. Of those, one inhibitor, BIX-01294 (diazepinquinazolin-amine derivative), does not compete with the cofactor S-adenosyl-methionine, and selectively impairs the G9a HMTase and the generation of H3K9me2 in vitro. In cellular assays, transient incubation of several cell lines with BIX-01 294 lowers bulk H3K9me2 levels that are restored upon removal of the inhibitor. Importantly, chromatin immunoprecipitation at several G9a target genes demonstrates reversible reduction of promoter-proximal H3K9me2 in inhibitor-treated mouse ES cells and fibroblasts. Our data identify a biologically active HMTase inhibitor that allows for the transient modulation of H3K9me2 marks in mammalian chromatin.
引用
收藏
页码:473 / 481
页数:9
相关论文
共 31 条
[1]   Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? [J].
Baylin, SB ;
Ohm, JE .
NATURE REVIEWS CANCER, 2006, 6 (02) :107-116
[2]   Small molecule regulators of protein arginine methyltransferases [J].
Cheng, DH ;
Yadav, N ;
King, RW ;
Swanson, MS ;
Weinstein, EJ ;
Bedford, MT .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (23) :23892-23899
[3]   Preferential response of cancer cells to zebularine [J].
Cheng, JC ;
Yoo, CB ;
Weisenberger, DJ ;
Chuang, J ;
Wozniak, C ;
Liang, GN ;
Marquez, VE ;
Greer, S ;
Orntoft, TF ;
Thykjaer, T ;
Jones, PA .
CANCER CELL, 2004, 6 (02) :151-158
[4]   G9a-mediated irreversible epigenetic inactivation of Oct-3/4 during early embryogenesis [J].
Feldman, N ;
Gerson, A ;
Fang, J ;
Li, E ;
Zhang, Y ;
Shinkai, Y ;
Cedar, H ;
Bergman, Y .
NATURE CELL BIOLOGY, 2006, 8 (02) :188-U55
[5]   Histone deacetylase inhibitors: A review of their clinical status as antineoplastic agents [J].
Garcia-Manero, G ;
Issa, JP .
CANCER INVESTIGATION, 2005, 23 (07) :635-642
[6]   Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms [J].
Gore, SD ;
Baylin, S ;
Sugar, E ;
Carraway, H ;
Miller, CB ;
Carducci, M ;
Grever, M ;
Galm, O ;
Dauses, T ;
Karp, JE ;
Rudek, MA ;
Zhao, M ;
Smith, BD ;
Manning, J ;
Jiemjit, A ;
Dover, G ;
Mays, A ;
Zwiebel, J ;
Murgo, A ;
Weng, LJ ;
Herman, JG .
CANCER RESEARCH, 2006, 66 (12) :6361-6369
[7]   Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9 [J].
Greiner, D ;
Bonaldi, T ;
Eskeland, R ;
Roemer, E ;
Imhof, A .
NATURE CHEMICAL BIOLOGY, 2005, 1 (03) :143-145
[8]   Nuclear transplantation, embryonic stem cells and the potential for cell therapy [J].
Hochedlinger, K ;
Rideout, WM ;
Kyba, M ;
Daley, GQ ;
Blelloch, R ;
Jaenisch, R .
HEMATOLOGY JOURNAL, 2004, 5 :S114-S117
[9]   Histone methyltransferases, diet nutrients and tumour suppressors [J].
Huang, S .
NATURE REVIEWS CANCER, 2002, 2 (06) :469-476
[10]   The epigenetic magic of histone lysine methylation [J].
Jenuwein, Thomas .
FEBS JOURNAL, 2006, 273 (14) :3121-3135